<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="33567">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02037919</url>
  </required_header>
  <id_info>
    <org_study_id>IIS#50302: Women's Health MISP</org_study_id>
    <nct_id>NCT02037919</nct_id>
  </id_info>
  <brief_title>Nexplanon Application Post-Abortion</brief_title>
  <acronym>NAPA</acronym>
  <official_title>Immediate vs. Delayed Insertion of Nexplanon After Termination of Pregnancy Over 14-weeks Gestation (NAPA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Women who receive Nexplanon immediately post abortion will be significantly more likely to
      be using the device 6 months after the procedure than those assigned to receive the device
      2-4 weeks after the procedure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Women will be contacted 6 months after their abortion to ask about contraception use and
      side effects.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research</study_design>
  <primary_outcome>
    <measure>Nexplanon use</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Current use of Nexplanon, confirmed via phone by participant palpation, at 6 months post-insertion.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Repeat pregnancy</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Occurrence of a pregnancy within 6 months after second-trimester abortion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side-effects of Nexplanon use</measure>
    <time_frame>6 mo.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Qualitative and quantitative self-reports of common side-effects of Nexplanon use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contraceptive method satisfaction</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Satisfaction with contraceptive method, as assessed by a Satisfaction Questionnaire, at 6 months post-abortion.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Contraception</condition>
  <condition>Abortion, Therapeutic</condition>
  <arm_group>
    <arm_group_label>Immediate Nexplanon Insertion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>An etonogestrel rod will be placed within 15 minutes following the abortion procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Post-op Nexplanon Insertion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants in the &quot;delayed&quot; placement group will be asked to return to Magee-Womens Hospital for a post-abortion visit 2-4 weeks following the procedure. Participants in the delayed group will be offered a method of contraception to use in the interim between their procedure and their insertion appointment.  At this time an etonogestrel rod will be placed in her arm using standard procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Immediate Nexplanon Insertion</intervention_name>
    <description>Patient will have a Nexplanon inserted within 15 minutes of her abortion</description>
    <arm_group_label>Immediate Nexplanon Insertion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Post-op Nexplanon Insertion</intervention_name>
    <description>Place Nexplanon at post operative visit  rather than at surgery</description>
    <arm_group_label>Post-op Nexplanon Insertion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age and older,

          -  an intrauterine pregnancy &gt; 14 weeks and &lt;23 6/7 weeks gestation and desire
             termination of pregnancy

          -  desire a Nexplanon for contraception

          -  able to give informed consent in English

          -  no contraindications to Nexplanon (based on U.S. CDC Medical Eligibility Criteria for
             Contraception) or D&amp;E

        Exclusion Criteria:

          -  unable to give informed consent

          -  have any of the following medical conditions: active venous thromboembolism, known or
             suspected sex-steroid sensitive malignancies, current hepatic disease with abnormal
             liver function tests, undiagnosed vaginal bleeding, hypersensitivity to any of the
             ingredients in Nexplanon.

          -  non-surgical management of pregnancy

          -  prior participation in this study

          -  breast cancer or a history of breast cancer
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miriam Cremer, MD,MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Melissa Gilmore Fann, MPH</last_name>
    <phone>412-641-5533</phone>
    <email>gilmoremn@upmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kristen Kamp, MPH</last_name>
    <phone>412-760-0243</phone>
    <email>kristenkamp@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 14, 2014</lastchanged_date>
  <firstreceived_date>January 14, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Miriam Cremer</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>3-keto-desogestrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
